Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Naomi Kamau

Naomi Kamau

Naomi Kamau

Clinical Trial Manager

Naomi is a Clinical Trial Manager within the Nuffield Department of Primary Care Health, University of Oxford, currently managing the DURATION UTI trial. She joined the Clinical Trials Unit in October 2022 as a Trial Manager for DURATION UTI, a study that is evaluating the shortest antibiotic treatment duration needed to effectively treat urinary tract infections (UTI) in women.

Before joining the department, Naomi worked on multiple vaccine trials as a Clinical Trial Coordinator at the Kenya Medical Research Institute's Centre for Geographic Medicine Research Coast (KEMRI-CGMRC) at Kilifi, Kenya.

As a Trial Coordinator, she managed several multicentre trials within Kenya and in Uganda sponsored by the University of Oxford and MSF Epicentre in France. Here, her roles involved the delivery of trials within time, budget, and scope, stakeholder engagement, and ensuring delivery of quality study results. 

These trials include A phase 1b/II ChAdOx1 nCoV-19 Vaccine trial evaluating the safety, immunogenicity, and efficacy of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19 in adults in Kenya; two Phase IV Yellow Fever vaccine studies evaluating the immunogenicity and safety of fractional doses of Yellow Fever vaccines in Kenya and Uganda namely YEFE and NIFTY; and a Phase I Rift Valley Fever Virus (RVFV) vaccine trial (ChAdOx1 RVF) evaluating the safety and efficacy of the new Rift Valley Fever vaccine.